HEPION PHARMACEUTICALS, INC. Restructuring and Related Cost, Expected Number of Positions Eliminated
HEPION PHARMACEUTICALS, INC. (HEPA) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 6 employee for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-21.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2025-04-08
- HEPION PHARMACEUTICALS, INC. restructuring and related cost, expected number of positions eliminated for the quarter ending 2024-03-31 was 6.00 employee.
employee
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|
| 2024-03-31 | 6.00 employee 10-Q · filed 2024-05-21 | |
| 2023-12-31 | 6.00 employee 10-Q · filed 2024-05-21 |
Integer
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|
| 2024-03-31 | 6.00 Integer 10-Q · filed 2024-08-13 | |
| 2023-12-31 | 6.00 Integer 10-Q · filed 2024-08-13 |
Employee
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month | Restructuring and Related Cost, Expected Number of Positions Eliminated 12 month |
|---|---|---|
| 2024-03-31 | 6.00 Employee 10-Q · filed 2024-11-14 | |
| 2023-12-31 | 6.00 Employee 10-K · filed 2025-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |